Open AccessDupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP
Author(s) -
Claus Bachert,
S. James Zinreich,
Peter Hellings,
Joaquim Mullol,
Daniel L. Hamilos,
Philippe Gevaert,
Robert M. Naclerio,
Nikhil Amin,
Vijay N. Joish,
Chunpeng Fan,
Donghui Zhang,
Heribert Staudinger,
Gianluca Pirozzi,
Neil M.H. Graham,
Asif Khan,
Leda Mannent
Publication year - 2019
Publication title -
rhinology (amsterdam. online)/rhinology
Language(s) - English
Resource type - Journals
eISSN - 1996-8604
pISSN - 0300-0729
DOI - 10.4193/rhin18.282
Subject(s) - dupilumab , medicine , nasal polyps , placebo , chronic rhinosinusitis , sinusitis , adverse effect , gastroenterology , quality of life (healthcare) , nose , surgery , pathology , asthma , alternative medicine , nursing
Chronic rhinosinusitis with nasal polyposis (CRSwNP) is associated with substantial sinus opacification. In a phase 2a study (NCT01920893), dupilumab, a fully human anti-IL-4Rα monoclonal antibody, improved outcomes in CRSwNP refractory to intranasal corticosteroids. We evaluated dupilumab’s effect on sinus opacification in relation to effects on nasal polyp burden, symptoms, and health-related quality of life (HRQoL) in patients with CRSwNP.